Clinical Trial Update: Efficacy and Durability of a Personalized Treat-and-extend Regimen of Faricimab for Treatment-naive Polypoidal Choroidal Vasculopathy [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial update reports on evaluating a personalized treat-and-extend regimen of Faricimab for treatment-naive polypoidal choroidal vasculopathy…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration
• Polypoidal Choroidal Vasculopathy

Drugs mentioned

• Faricimab (faricimab)

Snippet

Sponsor: Yeungnam University College of Medicine | Conditions: Polypoidal Choroidal Vasculopathy (PCV), Age Related Macular Degeneration | Phase 3 | Status: RECRUITING